{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T01:24:59Z","timestamp":1767921899890,"version":"3.49.0"},"reference-count":33,"publisher":"Portland Press Ltd.","issue":"6","license":[{"start":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T00:00:00Z","timestamp":1589414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,6,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>To date there is no effective treatment for pregnancies complicated by fetal growth restriction (FGR). Salvia miltiorrhiza, a traditional Chinese herb has been shown to promote blood flow and improve microcirculatory disturbance. In this pilot study, we evaluated whether S. miltiorrhiza can potentially become a possible therapy for FGR. Nineteen pregnant women with FGR were treated with S. miltiorrhiza and ATP supplementation for an average of 7 days, and 17 cases received ATP supplementation as controls. The estimated fetal weights (EFWs) were measured by ultrasound after treatment, and the birthweights were recorded after birth. After treatment with S. miltiorrhiza, 7 (37%) FGR cases showed an increase in EFW to above the 10th percentile, compared with 4 (23%) FGR cases in controls (odds ratio: 1.896, 95% confidence limits (CLs): 0.44\u20138.144). At delivery, 10 (53%) FGR cases in the treatment group delivered babies with a birthweight above the 10th percentile, compared with 6 (35%) FGR cases in the control group (odds ratio: 2.037, 95% CL: 0.532\u20137.793); 80 or 64% FGR cases in the treatment group showed an increase in fetal abdominal circumference (AC) or biparietal diameter (BPD) above the 10th percentile before delivery. While 44 or 30% FGR cases in the control group showed an increase in AC or BPD. No improvement of head circumference (HC) or femur length (FL) was seen. These pilot data suggest the need for multicenter randomized clinical trials on the potential of S. miltiorrhiza to improve perinatal outcome in pregnant women complicated by FGR.<\/jats:p>","DOI":"10.1042\/bsr20201222","type":"journal-article","created":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T21:56:53Z","timestamp":1589493413000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A pilot study on investigating the role of <i>Salvia miltiorrhiza<\/i> in fetal growth restriction"],"prefix":"10.1042","volume":"40","author":[{"given":"Fanghua","family":"Shen","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Suzhou Ninth People\u2019s Hospital, Suzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongdao","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Suzhou Ninth People\u2019s Hospital, Suzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Suzhou Ninth People\u2019s Hospital, Suzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandy","family":"Lau","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, The University of Auckland, Auckland, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Guo","sequence":"additional","affiliation":[{"name":"The Hospital of Obstetrics and Gynaecology, Fudan University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5894-6331","authenticated-orcid":false,"given":"Qi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, The University of Auckland, Auckland, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2020,6,3]]},"reference":[{"key":"2021111620122416300_B1","doi-asserted-by":"publisher","first-page":"f108","DOI":"10.1136\/bmj.f108","article-title":"Maternal and fetal risk factors for stillbirth: population based study","volume":"346","author":"Gardosi","year":"2013","journal-title":"BMJ"},{"key":"2021111620122416300_B2","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/jpc.13808","article-title":"Three-dimensional ultrasound cranial imaging and early neurodevelopment in preterm growth-restricted infants","volume":"54","author":"McLean","year":"2018","journal-title":"J. Paediatr. Child Health"},{"key":"2021111620122416300_B3","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1159\/000353631","article-title":"Neurodevelopment after fetal growth restriction","volume":"36","author":"Baschat","year":"2014","journal-title":"Fetal Diagn. Ther."},{"key":"2021111620122416300_B4","doi-asserted-by":"publisher","first-page":"S829","DOI":"10.1016\/j.ajog.2017.11.565","article-title":"The role of aspirin, heparin, and other interventions in the prevention and treatment of fetal growth restriction","volume":"218","author":"Groom","year":"2018","journal-title":"Am. J. Obstet. Gynecol."},{"key":"2021111620122416300_B5","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1097\/AOG.0b013e318293f12f","article-title":"\u201cTherapeutic\u201d bed rest in pregnancy: unethical and unsupported by data","volume":"121","author":"McCall","year":"2013","journal-title":"Obstet. Gynecol."},{"key":"2021111620122416300_B6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jep.2007.09.025","article-title":"Tanshinone IIA downregulates the CD40 expression and decreases MMP-2 activity on atherosclerosis induced by high fatty diet in rabbit","volume":"115","author":"Fang","year":"2008","journal-title":"J. Ethnopharmacol."},{"key":"2021111620122416300_B7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1142\/S0192415X15500020","article-title":"Compound Danshen (Salvia miltiorrhiza) dripping pill for coronary heart disease: an overview of systematic reviews","volume":"43","author":"Luo","year":"2015","journal-title":"Am. J. Chin. Med."},{"key":"2021111620122416300_B8","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/aps.2012.126","article-title":"Pharmacological actions and therapeutic applications of Salvia miltiorrhiza depside salt and its active components","volume":"33","author":"Wu","year":"2012","journal-title":"Acta Pharmacol. Sin."},{"key":"2021111620122416300_B9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1749-8546-1-3","article-title":"Preclinical and clinical examinations of Salvia miltiorrhiza and its tanshinones in ischemic conditions","volume":"1","author":"Adams","year":"2006","journal-title":"Chinese Med."},{"key":"2021111620122416300_B10","doi-asserted-by":"publisher","first-page":"CD004295","DOI":"10.1002\/14651858.CD004295","article-title":"Dan Shen agents for acute ischaemic stroke","author":"Wu","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"key":"2021111620122416300_B11","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.2174\/1381612822666161010105242","article-title":"Salvia miltiorrhiza: a potential red light to the development of cardiovascular diseases","volume":"23","author":"Wang","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"2021111620122416300_B12","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S0162-3109(00)00256-3","article-title":"Inhibition of interleukin-12 and interferon-gamma production in immune cells by tanshinones from Salvia miltiorrhiza","volume":"49","author":"Kang","year":"2000","journal-title":"Immunopharmacology"},{"key":"2021111620122416300_B13","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1055\/s-2003-45157","article-title":"Tanshinone IIA from Salvia miltiorrhiza inhibits inducible nitric oxide synthase expression and production of TNF-alpha, IL-1beta and IL-6 in activated RAW 264.7 cells","volume":"69","author":"Jang","year":"2003","journal-title":"Planta Med."},{"key":"2021111620122416300_B14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1749-8546-5-22","article-title":"Pharmacological effects of Salvia miltiorrhiza (Danshen) on cerebral infarction","volume":"5","author":"Lin","year":"2010","journal-title":"Chinese Med."},{"key":"2021111620122416300_B15","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1177\/0091270005282630","article-title":"Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use","volume":"45","author":"Zhou","year":"2005","journal-title":"J. Clin. Pharmacol."},{"key":"2021111620122416300_B16","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1345\/aph.19029","article-title":"Interaction between warfarin and danshen (Salvia miltiorrhiza)","volume":"35","author":"Chan","year":"2001","journal-title":"Ann. Pharmacother."},{"key":"2021111620122416300_B17","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/uog.19186","article-title":"Clinicians should stop prescribing sildenafil for fetal growth restriction (FGR): comment from the STRIDER Consortium","volume":"52","author":"Groom","year":"2018","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"2021111620122416300_B18","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1084\/jem.20130295","article-title":"Inflammation in rat pregnancy inhibits spiral artery remodeling leading to fetal growth restriction and features of preeclampsia","volume":"211","author":"Cotechini","year":"2014","journal-title":"J. Exp. Med."},{"key":"2021111620122416300_B19","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.4049\/jimmunol.1002679","article-title":"Spontaneous pregnancy loss mediated by abnormal maternal inflammation in rats is linked to deficient uteroplacental perfusion","volume":"186","author":"Renaud","year":"2011","journal-title":"J. Immunol."},{"key":"2021111620122416300_B20","doi-asserted-by":"publisher","first-page":"e1002220","DOI":"10.1371\/journal.pmed.1002220","article-title":"The World Health Organization Fetal Growth Charts: a multinational longitudinal study of ultrasound biometric measurements and estimated fetal weight","volume":"14","author":"Kiserud","year":"2017","journal-title":"PLoS Med."},{"key":"2021111620122416300_B21","first-page":"68","article-title":"Investigation on treatment of fetal growth restriction by salvia injection combined with composite amino acid","volume":"29","author":"Li","year":"2009","journal-title":"Zhongguo Zhong Xi Yi Jie He Za Zhi"},{"key":"2021111620122416300_B22","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/uog.4019","article-title":"Estimation of fetal weight: reference range at 20-36 weeks\u2019 gestation and comparison with actual birth-weight reference range","volume":"29","author":"Salomon","year":"2007","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"2021111620122416300_B23","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1097\/01.AOG.0000429658.85846.f9","article-title":"ACOG Practice bulletin no. 134: fetal growth restriction","volume":"121","author":"The American College of Obstetricians and Gynecologists","year":"2013","journal-title":"Obstet. Gynecol."},{"key":"2021111620122416300_B24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S1701-2163(16)35129-5","article-title":"Screening, diagnosis, and management of intrauterine growth restriction","volume":"34","author":"Lausman","year":"2012","journal-title":"J. Obstet. Gynaecol. Can."},{"key":"2021111620122416300_B25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejogrb.2015.06.021","article-title":"Fetal growth restriction and intra-uterine growth restriction: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians","volume":"193","author":"Vayssiere","year":"2015","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"2021111620122416300_B26","doi-asserted-by":"publisher","first-page":"e0034","DOI":"10.5041\/RMMJ.10168","article-title":"Coagulation and placenta-mediated complications","volume":"5","author":"Greer","year":"2014","journal-title":"Rambam Maimonides Med. J."},{"key":"2021111620122416300_B27","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/uog.13190","article-title":"Perinatal morbidity and mortality in early-onset fetal growth restriction: cohort outcomes of the trial of randomized umbilical and fetal flow in Europe (TRUFFLE)","volume":"42","author":"Lees","year":"2013","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"2021111620122416300_B28","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/j.1471-0528.2010.02879.x","article-title":"Sildenafil citrate therapy for severe early-onset intrauterine growth restriction","volume":"118","author":"von Dadelszen","year":"2011","journal-title":"BJOG"},{"key":"2021111620122416300_B29","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.3748\/wjg.v13.i26.3581","article-title":"Compound Danshen injection improves endotoxin-induced microcirculatory disturbance in rat mesentery","volume":"13","author":"Han","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"2021111620122416300_B30","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2147\/TCRM.S2527","article-title":"Treating oligohydramnios with extract of Salvia miltiorrhiza: a randomized control trial","volume":"4","author":"Chu","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"key":"2021111620122416300_B31","first-page":"969","article-title":"Ligustrazine and Salvia miltiorrhiza injection solution in complementary therapy of pregnancy-induced hypertension: clinical analysis of 60 cases","volume":"23","author":"Wang","year":"2003","journal-title":"Di 1 jun yi da xue xue bao = Academic J. First Med. College of PLA"},{"key":"2021111620122416300_B32","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ijcard.2010.12.073","article-title":"Is danshen (Salvia miltiorrhiza) dripping pill more effective than isosorbide dinitrate in treating angina pectoris? A systematic review of randomized controlled trials","volume":"157","author":"Jia","year":"2012","journal-title":"Int. J. Cardiol."},{"key":"2021111620122416300_B33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1749-8546-1-3","article-title":"Preclinical and clinical examinations of Salvia miltiorrhiza and its tanshinones in ischemic conditions","volume":"1","author":"Adams","year":"2006","journal-title":"Chinese Med"}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20201222\/883024\/bsr-2020-1222.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20201222\/883024\/bsr-2020-1222.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T20:47:25Z","timestamp":1637095645000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/40\/6\/BSR20201222\/224149\/A-pilot-study-on-investigating-the-role-of-Salvia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6,26]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20201222","relation":{},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"value":"0144-8463","type":"print"},{"value":"1573-4935","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,6]]},"published":{"date-parts":[[2020,6]]},"article-number":"BSR20201222"}}